D3 Bio

Executive Summary

D3 Bio is a preclinical-stage biotechnology company leveraging a data-driven, patient-centric approach to develop novel biologics for oncology and immunology. Founded in 2021 and headquartered in San Diego, the company has raised $108 million to date. Its strategy focuses on identifying and validating novel targets with strong biological rationale, aiming to design differentiated therapies that improve patient outcomes. D3 Bio's translational insights and emphasis on data-driven discovery position it to address unmet medical needs in both oncology and immunology. As a private company with a lean team and no commercial products, its near-term value hinges on advancing its pipeline toward clinical development.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead program40% success
• H2 2026Preclinical proof-of-concept data presentation60% success
• TBDPotential partnership or licensing deal30% success